TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in hormonal profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall and task-relevant neural separability in lateral prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral multitasking cost
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spasticity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of time of plasma glucose concentrations spent in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Saliva Potential of Hydrogen (pH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPRS for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Mouth opening (Inter- incisal Rural)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sudden cardiac death / lethal arrhythmia
Endpoint domain: Mortality/survival
Primary endpoint: Myocardial infarction or death attributable to myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Discontinue rate caused by any AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of Malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heme Oxygenase-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete healing at 6 months of follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time elapsed between start of the study and complete healing of the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall gastrointestinal (GI) tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC 0-12) of Capivasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of Capivasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life (t1/2) of Capivasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulation ratio (Rac) of Capivasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of pH-Rhodo-positive alveolar macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Valve re-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: endoscopic hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Boston Carpal Tunnel Syndrome Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diameter of Thoracic duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events at 1 year
Endpoint domain: Adverse events/effects
Primary endpoint: Hemoglobin Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Erythrocyte Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Leukocyte Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of venetoclax
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of creating an electroanatomical map
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance to radiotherapy treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with (serious) adverse events (of special interest)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with abnormal laboratory test results or vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of ETDRS letter count for BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-lesional skin tape transcriptome at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Responsiveness Scale - Adult version (SRS-A)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Attachment Styles Questionnaire (ASQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportions of simultaneous responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptation Difficulty Assessment Scale in the Elderly
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Life Satisfaction Scale for the Elderly
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Psychological Well-Being Scale in the Elderly
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Height Intolerance Severity Scale (vHISS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity Measure for Specific Phobia-Adult (SMSP-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The IAPT phobia scale-avoidance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intra-class correlation coefficient of inversion force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhythmicity of melatonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change from baseline in cannabis use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Events Free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of AEs following administration of G03-52-01
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of SAEs following administration of G03-52-01
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with target protective concentration (NAC) value > 0.02 U/mL (BoNT/A) or > 0.03 U/mL (BoNT/B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUCinf) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative fixation outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of function independent
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Walking speed in meters per second
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerobic capacity and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute gastrointestinal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acute genitourinary toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in self-reported rate of hair growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: LTC home readiness and capacity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of time to complete PREVENT Program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Circuit Primary Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Met the Markedly Abnormal Criteria for Vital Sign Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Met the Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Met the Markedly Abnormal Criteria for Laboratory Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limiting toxicities to establish the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the laboratory safety values from baseline to end of safety follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical site infections requiring secondary closure
Endpoint domain: Adverse events/effects
Primary endpoint: Reliability of 4-meter walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of 10-meter walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sensitivity and specificity of the AI system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the duration of venous valve regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Status of Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Visual Analogue Score for Leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of use of antiarrhythmic drugs in pediatrics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference of antibody levels between study groups by month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants with suspected clinically reported severe COVID-19 disease or evidence of SARS-CoV-2 exposure between study groups by month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of SARS-CoV-2 breakthrough infections in previously exposed/vaccinated participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Severity of Pseudoexfoliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in annual bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the scores of HR-QoL tools CHO-KLAT and EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction of the parents about the treatment with Emicizumab
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of remifentanil induced cough
Endpoint domain: Adverse events/effects
Primary endpoint: Presence or absence of capsules and/or transit markers in ostomy fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neurophysiological marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit to stand repetitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased NT-proBNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Kinematics of the gait cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Insulin Aspart Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Curve (AUC) of Insulin Aspart Serum Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum Serum Human Insulin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Curve (AUC) of Human Insulin Serum Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum Glucose Infusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of Pathological Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Major Pathological Response (mPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Partial Pathological Response (pPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Timed Up And Go (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 Times Sit To Stand Test (5XSST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis accuracy of ileocolic intussusception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Distribution of histologic subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-exercise CrCEST recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time in range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with preoperative medical preparation instructions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Reliability of Q-angle measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concurrent validity of Q-angle measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Morning Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Dehydroepiandrosterone (DHEA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time between acute pancreatitis diagnosis and EPI diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of successful treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects according to Medical Dictionary for Regulatory Activities
Endpoint domain: Adverse events/effects
Primary endpoint: Time from starting PERT to normalization of exocrine pancreatic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in QuickDASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in BCTQ-S
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in hand grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in pinch strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Participant perception of change in overall physical condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in military work status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Identification of biliary structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Family Caregiver Burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Histologic remission of UC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: radical tumor resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of postoperative hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Exclusive Lactation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg strength and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall response rate (CR + R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curative effect prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin irritation assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: initiation of organ support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular displacement of spine during baseball batting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular displacement of hip during baseball batting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular velocity of spine during baseball batting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular velocity of hip during baseball batting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracic spine mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSD performance data with detection by RT-PCR and at-home assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline renin to predict norepinephrine equivalent dose (NED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline DPP3 to predict norepinephrine equivalent dose (NED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall rate of responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful device usage
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lung parenchymal involvement evaluated by lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Paraseptal and/or panlobular emphysema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Computed tomographic features and patterns of interstitial lung diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Glioblastoma Survival Rates
Endpoint domain: Mortality/survival
Primary endpoint: Time to epithelialization of the skin wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Observation of scar formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Zarit Burden Interview (ZBI)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Pelvic floor Impact Questionnaire (PFIQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional pelvic pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Pathologic Response of Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number and size of bare spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women with migration of gel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteins creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing time of the donor sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appendicular Skeletal Muscle Index (ASMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Disease Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Connectivity alterations of brain networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative excretion of 14C-labeled drug-related material
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distribution of radioactivity in whole blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain of fear for children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain of fear for parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Harmonic Ratio (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEG spectral power of the alpha band activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Functional Connectivity based on EEG signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mammography uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Colonic residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum alemtuzumab concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes